Abstract:Background Kabuki syndrome type 1 (KS1), a rare multisystem congenital disorder, presents with characteristic facial features, intellectual disability, persistent fetal fingertip pads, skeletal abnormalities, and postnatal growth delays. KS1 results from pathogenic variants in the KMT2D gene, which encodes a histone methyltransferase protein involved in chromatin remodeling, promoter and enhancer regulation, and scaffold formation during early development. KMT2D also mediates cell signaling pathways, responding to external stimuli and organizing effector protein assembly. Research on KMT2D's molecular mechanisms in KS1 has primarily focused on its histone methyltransferase activity, leaving a gap in understanding the methyltransferase‐independent roles in KS1 clinical manifestations. Methods This scoping review examines KMT2D's role in gene expression regulation across various species, cell types, and contexts. We analyzed human pathogenic KMT2D variants using publicly available databases and compared them to research organism models of KS1. We also conducted a systematic search of healthcare and governmental databases for clinical trials, studies, and therapeutic approaches. Results Our review highlights KMT2D's critical roles beyond methyltransferase activity in diverse cellular contexts and conditions. We identified six distinct groups of KMT2D as a cell signaling mediator, including evidence of methyltransferase‐dependent and ‐independent activity. A comprehensive search of the literature, clinical databases, and public registries emphasizes the need for basic research on KMT2D's functional complexity and longitudinal studies of KS1 patients to establish objective outcome measurements for therapeutic development. Conclusion We discuss how KMT2D's role in translating external cellular communication can partly explain the clinical heterogeneity observed in KS1 patients. Additionally, we summarize the current molecular diagnostic approaches and clinical trials targeting KS1. This review is a resource for patient advocacy groups, researchers, and physicians to support KS1 diagnosis and therapeutic development.

Characterizing the molecular impact of KMT2D variants on the epigenetic and transcriptional landscapes in Kabuki Syndrome

Integrated Facial Analysis and Targeted Sequencing Identifies a Novel KDM6A Pathogenic Variant Resulting in Kabuki Syndrome

Molecular insights of KMT2D and clinical aspects of Kabuki syndrome type 1

Identification of Novel KMT2D Mutations in Two Chinese Children with Kabuki Syndrome: a Case Report and Systematic Literature Review

Kabuki syndrome: review of the clinical features, diagnosis and epigenetic mechanisms

UTX-guided Neural Crest Function Underlies Craniofacial Features of Kabuki Syndrome.

DNA methylation profiling in Kabuki syndrome: reclassification of germline KMT2D VUS and sensitivity in validating postzygotic mosaicism

The KMT2D Kabuki syndrome histone methylase controls neural crest cell differentiation and facial morphology

[Two Novel and De Novo KMT2D Mutations on the Same Allele Cause Kabuki Syndrome].

Kabuki Syndrome: Novel Pathogenic Variants, New Phenotypes and Review of Literature

Patients with a Kabuki Syndrome Phenotype Demonstrate DNA Methylation Abnormalities

Kabuki Syndrome Stem Cell Models Reveal Locus Specificity of Histone Methyltransferase 2D (KMT2D/MLL4).

KMT2D regulates activation, localization, and integrin expression by T-cells

Clinical and molecular characteristics of Kabuki syndrome patients with missense variants-novel features and literature review

KMT2D Histone Methyltransferase Modulates Chromatin Accessibility During Regulatory T Cell Development (LYM6P.714)

Clinical and molecular characteristics of Korean patients with Kabuki syndrome

Genetic and Phenotypic Spectrum of KMT2D Variants in Taiwanese Case Series of Kabuki Syndrome

RAP1-mediated MEK/ERK Pathway Defects in Kabuki Syndrome.

Case Report: A Study on the De Novo KMT2D Variant of Kabuki Syndrome with Goodpasture’s Syndrome by Whole Exome Sequencing

KMT2D deficiency leads to cellular developmental disorders and enhancer dysregulation in neural-crest-containing brain organoids

Mutation Update for Kabuki Syndrome Genes Kmt2d and Kdm6a and Further Delineation of X-Linked Kabuki Syndrome Subtype 2